
Aficamten's label now includes MAPLE-HCM data, in which aficamten monotherapy improved peak VO2 by 2.3 mL/kg/min more than metoprolol at 24 weeks.
Review the biggest gastroenterology news from the first half of 2026, including FDA updates, IBD advances, and key clinical trials.
The first half of 2026 delivered meaningful progress across






